Rho Capital Partners’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-3,766,666
| Closed | -$57.4M | – | 5 |
|
|
2022
Q1 | $57.4M | Hold |
3,766,666
| – | – | 39.74% | 2 |
|
|
2021
Q4 | $66.7M | Hold |
3,766,666
| – | – | 43.3% | 2 |
|
|
2021
Q3 | $79.2M | Hold |
3,766,666
| – | – | 44.14% | 2 |
|
|
2021
Q2 | $74.3M | Hold |
3,766,666
| – | – | 6.8% | 3 |
|
|
2021
Q1 | $109M | Hold |
3,766,666
| – | – | 10.53% | 3 |
|
|
2020
Q4 | $114M | Hold |
3,766,666
| – | – | 60.06% | 1 |
|
|
2020
Q3 | $59.9M | Hold |
3,766,666
| – | – | 49.9% | 1 |
|
|
2020
Q2 | $74.4M | Hold |
3,766,666
| – | – | 48.16% | 1 |
|
|
2020
Q1 | $46.4M | Hold |
3,766,666
| – | – | 46.79% | 1 |
|
|
2019
Q4 | $69.6M | Sell |
3,766,666
-1
| -0% | -$18 | 52.94% | 1 |
|
|
2019
Q3 | $52.2M | Hold |
3,766,667
| – | – | 43.68% | 2 |
|
|
2019
Q2 | $55.1M | Buy |
+3,766,667
| New | +$55.1M | 38.25% | 2 |
|